Insulet Corporation

NasdaqGS PODD

Insulet Corporation Price to Sales Ratio (P/S) on January 14, 2025: 10.33

Insulet Corporation Price to Sales Ratio (P/S) is 10.33 on January 14, 2025, a 25.73% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Insulet Corporation 52-week high Price to Sales Ratio (P/S) is 10.67 on November 11, 2024, which is 3.24% above the current Price to Sales Ratio (P/S).
Insulet Corporation 52-week low Price to Sales Ratio (P/S) is 6.33 on May 13, 2024, which is -38.77% below the current Price to Sales Ratio (P/S).
Insulet Corporation average Price to Sales Ratio (P/S) for the last 52 weeks is 8.12.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: PODD

Insulet Corporation

CEO	Dr. James R. Hollingshead Ph.D.
IPO Date	May 15, 2007
Location	United States
Headquarters	100 Nagog Park
Employees	3,000
Sector	Health Care
Industries Pharmaceuticals Medical Instruments

Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Key trends

Past 5 years